News Search Results

Displaying Results 1-25 of 4510 "biotechnology"

Feb 13, 2026, 17:36 ET QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.

investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.

More news about: Robbins LLP

Feb 13, 2026, 16:15 ET Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public

More news about: Nektar Therapeutics

Feb 13, 2026, 16:01 ET AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic

More news about: Amgen

Feb 13, 2026, 15:00 ET Sphingolipids Market Forecast 2025-2035: Global Value to Reach USD 1,145.6 Million by 2035 at 5.1% CAGR

Bioparticles; Croda International (SphingoCare™); Merck KGaA; CordenPharma International; Lipoid GmbH; Biosynth; LARODAN AB; Santa Cruz Biotechnology, Inc.; Creative Enzymes; and others.Croda's SphingoCare™ range highlights ongoing expansion in cosmetic-grade sphingolipids and ceramide-based

More news about: Future Market Insights

Feb 13, 2026, 10:30 ET Cleanroom Technologies Market worth $ 12.93 billion by 2031 | MarketsandMarkets™

technological, and industry-specific aspects, are collectively driving the growth of cleanroom technologies. Manufacturers of pharmaceuticals, biotechnology, and medical devices are investing in advanced contamination-control systems, such as isolators, modular cleanrooms, and real-time monitoring solutions,

More news about: MarketsandMarkets

Feb 13, 2026, 09:12 ET Soin Neuroscience and Lilac Biosciences Launch Collaboration to Study RNA Signatures in Pain and Neuromodulation

PROVIDENCE, R.I. and DAYTON, Ohio, Feb. 13, 2026 /PRNewswire/ -- Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical tools, announced a research collaboration

More news about: Soin Neuroscience

Feb 13, 2026, 08:58 ET Intensity Therapeutics Announces Reverse Stock Split

Feb. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system

More news about: Intensity Therapeutics Inc.

Feb 13, 2026, 08:31 ET Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

Lunai BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-powered biotech and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can

More news about: Lunai Bioworks Inc.

Feb 13, 2026, 08:31 ET MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset

More news about: MetaVia Inc.

Feb 13, 2026, 06:30 ET Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private

More news about: Immunic, Inc.

Feb 13, 2026, 01:04 ET HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration

More news about: HanchorBio Inc.

Feb 12, 2026, 16:05 ET Vasa Therapeutics Announces Participation at the 36th Annual Oppenheimer Life Sciences Conference

Calif. and WROCLAW, Poland, Feb. 12, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced its participation at the 36th Annual Oppenheimer

More news about: Vasa Therapeutics

Feb 12, 2026, 16:05 ET BioMarin Announces Closing of Private Offering of Senior Notes

securities in any jurisdiction in contravention of applicable law.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based

More news about: BioMarin Pharmaceutical Inc.

Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO

[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,

More news about: Pomerantz LLP

Feb 12, 2026, 14:15 ET Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP

[email protected]. UNIQURE N.V. CLASS ACTION LAWSUIT COMPLAINT ALLEGEGATIONS uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease ("HD"). uniQure is incorporated in The Netherlands with its

More news about: Kessler Topaz Meltzer & Check, LLP

Feb 12, 2026, 10:45 ET Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 /PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced that the first participants

More news about: Centivax

Feb 12, 2026, 10:00 ET Yosemite Announces More Than $18 Million Deployed in Grants

example included preclinical research led by Craig Crews at Yale, which contributed to foundational insights behind the formation of Quarry Thera, a biotechnology company developing small molecule drugs that modulate protein interactions in completely novel ways to treat cancer and autoimmune diseases.Collaboration

More news about: Yosemite

Feb 12, 2026, 09:30 ET Timken Awards Scholarships Valued at up to $540,000 to 20 Students Around the World

Sylwester Struski and Edyta Struska from Czeladź, Poland. She plans to study medicine at the Medical University of Wrocław, specializing in surgery or biotechnology.Lana Mary Tom, daughter of senior system consultant Tom Chandy and Jyothi Jose from Christ Junior College in Bangalore, India. She

More news about: The Timken Company

Feb 12, 2026, 09:00 ET Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide

advancing toward the automated future of "lights-out laboratories."The industry widely recognizes that the deep integration of AI technology and biotechnology represents a key direction for the future of pharmaceutical R&D. In response, Sanyou Biopharmaceuticals is committed to building an intelligent

More news about: Sanyou Bio

Feb 12, 2026, 09:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS

best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic

More news about: Amgen

Feb 12, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences

PLYMOUTH MEETING, Pa., Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious

More news about: INOVIO Pharmaceuticals, Inc.

Feb 12, 2026, 08:00 ET Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers

—NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced the launch of Open Aperture, a material transfer

More news about: Apertura Gene Therapy

Feb 12, 2026, 07:30 ET Soligenix Details Recent Progress and Upcoming Milestones

procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will

More news about: SOLIGENIX, INC.

Feb 12, 2026, 06:59 ET Microbiology Testing Market worth $10.09 billion by 2031 | MarketsandMarkets™

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187005691 Microbiology testing is widely used across pharmaceutical manufacturing, biotechnology, food and beverage processing, water quality monitoring, and environmental applications. Market expansion is driven by rising demand for contamination